Sep 26, 2026The White House said the cuts target what it called "the most harmful government spending," with most reductions centered on Health and Human Services programs serving refugees and unaccompanied minors accused of being in the country illegally. Critics including Sen. Susan Collins and Sen. Patty Murray said the administration is illegally usurping Congress’ power of the purse.
The Catalyst Brief
Sep 26, 2026The nomination period for the next WHO director-general closed Thursday, with five candidates listed on the organization’s website, though additional names could still emerge before the official list is released in early November. The election is taking place as the WHO navigates cost-cutting, unpaid U.S. fees and a broader contraction in international global health spending.
The Catalyst Brief
Sep 25, 2026The warning letter lays out two separate lines of concern: contamination risk tied to site conditions and potential failure to meet Section 503A limits on copying commercial products. For the GLP-1 compounding market, the signal is that the agency is pressing both manufacturing conditions and the legal basis used to justify compounded semaglutide and tirzepatide.
The Catalyst Brief
Sep 24, 2026The hearing centered on institutional independence after senators cited Robert F. Kennedy Jr.’s past reversals under pressure from the president. Overton said the current MMR vaccine is safe and effective and pledged that advisory committees will meet at the FDA if she is confirmed, but she did not commit to preventing further shutdowns.
The Catalyst Brief
Sep 24, 2026The award ties government biodefense priorities to Flagship-founded platforms in vaccine design and protein discovery. Strategically, it shows how public countermeasure funding is being used to pull AI-enabled biotech tools into preparedness programs rather than funding a single product bet.
The Catalyst Brief
Sep 23, 2026Compass Therapeutics is trying to preserve its filing timeline for tovecimig even after the FDA recommended an additional study before review in advanced biliary tract cancer. The company argues that COMPANION-002 showed clinically meaningful activity, while Leerink Partners framed the situation as difficult but not unprecedented because the agency did not say a new trial was mandatory before filing.
The Catalyst Brief
Sep 22, 2026According to reports cited by Fierce, President Donald Trump met with senior officials in the Oval Office on Friday to discuss plans for a new commission with the power to block NIH grants that do not conform to the administration’s agenda. The move, if implemented, would extend a period of funding volatility that has already disrupted hundreds of clinical trials.
The Catalyst Brief
Sep 21, 2026Karim Mikhail, now permanent director of the Center for Biologics Evaluation and Research, said the aim is an adapted regulatory framework for rare diseases that is predictable rather than simply flexible. Michael Davis, now permanent director of the Center for Drug Evaluation and Research, was also viewed positively by RBC Capital Markets for rare disease and novel modalities.
The Catalyst Brief
Sep 20, 2026The appointments follow Kennedy’s dismissal of vice chairs John Wong and Esa Davis nearly four months ago, a period in which five other members’ terms expired without replacement and the previous chair left on his own. The immediate policy significance is less about one recommendation than about who now shapes a body whose preventive-care grades determine what payers must fully cover.
The Catalyst Brief
Sep 20, 2026STAT reports that attacks on hospitals and disrupted supply chains are stripping Sudan of cancer care capacity that once existed in places such as Khartoum, Darfur, and El Obeid. The immediate policy signal is that war damage and aid cuts are turning chronic illness into an acute access crisis, with survival increasingly determined by whether patients can physically reach one of the few remaining treatment sites.
The Catalyst Brief
Sep 20, 2026The new program asks organizations to submit tools and technologies that could make autism assessments faster while improving support for autistic people. The policy signal is a split-screen one: the administration is putting a high-profile federal research vehicle behind autism, while Kennedy’s own rhetoric and unsupported claims continue to create credibility risks around the broader agenda.
The Catalyst Brief
Sep 19, 2026A new policy announced Friday says members can decide for themselves whether to receive products derived from donated blood and treatments involving plasma, platelets, and red and white blood cells. The organization also now allows members to decide whether to donate blood for blood products, but it continues to oppose receiving or donating whole blood for transfusions.
The Catalyst Brief
